As per the research report, the size of the Asia Pacific Ulcerative Colitis Market is valued at USD 0.92 billion in 2021 and is projected to grow at a CAGR of 7.9%, to reach USD 1.34 billion by 2026 during the forecast period 2021 to 2026.
Ulcerative Colitis is an inflammatory bowel disease that results in ulcers and inflammation of the rectum and colon. The disease usually lasts long term and the symptoms include diarrhea with blood and abdominal pain. It can also result in inflammations in several body parts and can also lead to colon cancer.
The major factors that are fueling the growth of Asia Pacific ulcerative colitis market are the advent of better drugs, increasing incidence of ulcerative colitis, advanced drugs inflowing the market, increasing outlays towards research in mini-sized molecules, enhanced cure of inflammatory bowel ailments, expansion of patient pool due to unmet requirements, and incoming investments on large scale for R&D activities. The lack of personalized therapy, medication, and curative therapy are the major opportunities for the prosperity of the market.
Also, the people who are affected by ulcerative colitis disease are in millions leading to a boom of various segments operating in the market such as pharmacy and research and development which is very crucial to develop innovative and technically advanced therapies for treating ulcerative colitis. Government and private organizations are focusing more on biologics research and development; these factors are further likely to boost the growth of the ulcerative colitis market in the Asia Pacific region.
The developing countries like India are expanding the growth of the ulcerative colitis market owing to increasing number of people affected by ulcerative colitis. Also, rapid modernization and commercialization of the healthcare sector in India are leading to the expansion of the drug development industry are fueling the growth of the ulcerative colitis market in India which is eventually contributing to the growth of the ulcerative colitis market in the Asia Pacific.
The factors that are limiting the growth of the Asia pacific ulcerative colitis market and posing challenges to the stakeholders in the region are the patent expiry of drugs, increasing the propensity of common drugs whereas popular drugs are steadily losing the patent protection. Also, the process of approving the biosimilars is very slow due to the stringent regulations in different countries which are limiting the market growth in those particular Asia Pacific regions.
This research report segmented and sub-segmented into the following categories:
Proctosigmoiditis is the most common type of ulcerative colitis and hence it holds the major market share.
Asia Pacific is expected to be the fastest growing market. It is due to the developing healthcare sector in emerging countries such as India through government intervention and expansions of major pharmaceutical companies to this region. China is dominating the Asia Pacific ulcerative colitis market owing to factors such as advancements in the healthcare sector and the increasing economy of the nation. The market in India and China is likely to expand further during the forecast period owing to the increasing incidence of ulcerative colitis diseases, increasing investments from public and private organizations, rapid developments in healthcare facilities and infrastructure by the key players
The Top companies leading in the APAC Ulcerative Colitis Market profiled in the report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche and Shire Pharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Monoclonal Antibodies
5.1.2.1 Humira
5.1.2.2 Simponi
5.1.2.3 Remicade
5.1.2.4 Entyvio
5.1.3 Biosimilars
5.1.4 Pharmaceuticals
5.1.4.1 Mesalamine
5.1.4.1.1 Asacol HD
5.1.4.1.2 Pentasa
5.1.4.1.3 Lialda
5.1.4.1.4 sfRowasa
5.1.4.2 Balsazide
5.1.4.2.1 Colazal
5.1.4.2.2 Giazo
5.1.4.3 Budesonide
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Proctosigmoiditis
5.2.3 Ulcerative Proctitis
5.2.4 Pancolitis
5.2.5 Left-sided Colitis
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Route of Administration
5.3.1 Introduction
5.3.2 Oral
5.3.3 Injectable
5.3.4 Y-o-Y Growth Analysis, By Route of Administration
5.3.5 Market Attractiveness Analysis, By Route of Administration
5.3.6 Market Share Analysis, By Route of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Route of Administration
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Route of Administration
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Route of Administration
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 Pfizer
8.4 Takeda Pharmaceuticals
8.5 AbbVie
8.6 Johnson and Johnson
8.7 Merck
8.8 Sanofi
8.9 F. Hoffmann-La Roche
8.10 Shire Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
